Scenario
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK, focused on developing prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
AstraZeneca uses Questionmark assessments within the department of capabilities development to train on-field sales teams. Before implementing Questionmark, AstraZeneca was limited to paper assessments, which meant the businesses faced several challenges around security, complexity, and extra work.
For AstraZeneca, assessing the scientific knowledge of on-field sales teams was the priority, as well as increasing the security of assessments, lightening the workload, and simplifying the administrative process.
Solution
AstraZeneca chose Questionmark because of the simplicity of the system, the range of question types, and the deep reporting capabilities.
Questionmark now supports their business needs by delivering assessments, surveys, and quizzes to all employees across the full training and hiring lifecycle.
Reporting is used extensively across the business, with CSV-based data exports a key part of their workflow.
Discover our assessment solutions for Pharmaceutical and Life Science organizations here.
The results
AstraZeneca now has a reliable and integrated assessment system that supports annual employee training at scale, meeting both internal compliance needs and external requirements.
Ongoing platform capabilities, including full online delivery and SSO, have streamlined the experience for administrators and participants alike.
This software is very well integrated into our training tool. A reliable and solid assessment system that allows us, every year, to train our employees and meet internal and external demands. The improvements brought, over the years (e.g. fully online, SSO connection etc.), have allowed us to deploy a very simple use, both for participants and administrators.
Delphine Léveillé
AstraZeneca
